PTC Therapeutics, Inc. (NASDAQ:PTCT) Given Consensus Recommendation of “Hold” by Brokerages

PTC Therapeutics, Inc. (NASDAQ:PTCT) has been assigned an average recommendation of “Hold” from the fifteen analysts that are presently covering the stock, Marketbeat Ratings reports. Three equities research analysts have rated the stock with a sell recommendation, four have given a hold recommendation, seven have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price target among brokers that have covered the stock in the last year is $51.15.

PTCT has been the topic of several analyst reports. Raymond James assumed coverage on shares of PTC Therapeutics in a report on Thursday, October 10th. They issued a “market perform” rating on the stock. JPMorgan Chase & Co. raised their price objective on PTC Therapeutics from $51.00 to $62.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 19th. Barclays boosted their target price on PTC Therapeutics from $45.00 to $56.00 and gave the company an “equal weight” rating in a research note on Tuesday. UBS Group raised their price target on PTC Therapeutics from $47.00 to $71.00 and gave the stock a “buy” rating in a research report on Tuesday. Finally, StockNews.com cut PTC Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, November 19th.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. KBC Group NV lifted its position in PTC Therapeutics by 29.2% during the 3rd quarter. KBC Group NV now owns 2,232 shares of the biopharmaceutical company’s stock worth $83,000 after buying an additional 504 shares in the last quarter. CWM LLC raised its holdings in PTC Therapeutics by 354.7% during the third quarter. CWM LLC now owns 2,687 shares of the biopharmaceutical company’s stock worth $100,000 after acquiring an additional 2,096 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its position in PTC Therapeutics by 21.5% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,782 shares of the biopharmaceutical company’s stock valued at $104,000 after purchasing an additional 492 shares during the last quarter. Quest Partners LLC bought a new position in PTC Therapeutics in the second quarter valued at approximately $128,000. Finally, Quarry LP increased its position in shares of PTC Therapeutics by 100.0% during the 2nd quarter. Quarry LP now owns 5,000 shares of the biopharmaceutical company’s stock worth $153,000 after purchasing an additional 2,500 shares during the last quarter.

PTC Therapeutics Price Performance

Shares of PTCT stock opened at $50.29 on Wednesday. The stock has a market cap of $3.88 billion, a PE ratio of -8.47 and a beta of 0.63. The stock has a 50-day moving average of $40.80 and a 200-day moving average of $36.57. PTC Therapeutics has a one year low of $23.58 and a one year high of $54.16.

About PTC Therapeutics

PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.